Related Experiment Video

Updated: May 5, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

17.5K

Novel tyrosine kinase inhibitors for renal cell carcinoma

Tanya B Dorff1, Sumanta K Pal, David I Quinn

  • 1Department of Medicine, USC Keck School of Medicine, USC Norris Comprehensive Cancer Center, 1441 Eastlake Ave. #3440, Los Angeles, CA 90033, USA.

Expert Review of Clinical Pharmacology
|December 7, 2013
PubMed

Insights

New tyrosine kinase inhibitors targeting novel pathways like FGF, angiopoietin, and MET are in development for advanced renal cell carcinoma (RCC). These agents aim to overcome resistance and toxicity associated with current VEGF and mTOR therapies.

Area of Science:

  • Oncology
  • Pharmacology
  • Urology

Background:

  • Advanced renal cell carcinoma (RCC) treatment has been improved by targeted therapies against vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR).
  • However, drug resistance and toxicity necessitate the development of novel therapeutic agents for RCC.
  • Next-generation tyrosine kinase inhibitors (TKIs) are being developed with improved specificity and broader receptor inhibition.

Purpose of the Study:

  • To review emerging tyrosine kinase inhibitors (TKIs) for advanced renal cell carcinoma (RCC).
  • To highlight novel therapeutic strategies targeting pathways beyond VEGF and mTOR.
  • To discuss five specific TKIs under development for RCC treatment.

Main Methods:

  • Review of current literature on tyrosine kinase inhibitors in renal cell carcinoma (RCC) research.
  • Identification of novel receptor targets and pathways being investigated for RCC therapy.
  • Summary of five investigational TKIs: tivozanib, dovitinib, regorafenib, cabozantinib, and tivantinib.

Main Results:

  • Several novel TKIs are in development, targeting a wider range of receptors.
  • New pathways such as fibroblast growth factor (FGF), angiopoietin, and MET are being explored.
  • These agents aim to offer improved efficacy and safety profiles for advanced RCC.

Conclusions:

  • Targeting novel receptors and pathways with TKIs represents a promising future strategy for advanced RCC.
  • Investigational agents like tivozanib, dovitinib, regorafenib, cabozantinib, and tivantinib show potential.
  • Further research and clinical trials are essential to establish the role of these novel TKIs in RCC management.

More Related Videos

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers12:22

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

33.1K
Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

7.1K

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
689
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
15.5K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K